<DOC>
	<DOCNO>NCT00922701</DOCNO>
	<brief_summary>The development glucose-sparing strategy able provide efficacious ultrafiltration profile represent one modern goal peritoneal dialysis therapy . The study hypothesis evaluate possibility formulate peritoneal dialysis solution contain L-carnitine osmotic agent partially replace glucose .</brief_summary>
	<brief_title>L-Carnitine Peritoneal Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Dialysis Solutions</mesh_term>
	<criteria>Age â‰¥18 year Have diagnosis End Stage Renal Disease Continuous Ambulatory Peritoneal Dialysis least 3 month Be stable clinical condition four week immediately prior Screening Period demonstrate medical history , physical examination laboratory test Have blood hemoglobin concentration 8,5 g/100ml ( data verify Investigators ) Have experience peritonitis episode last 3 month Be treat 3 diurnal exchange bag solution ( 1.5 % 2.5 % glucose ) one nocturnal exchange bag solution ( 2.5 % glucose ) Have Kt/V urea measurement &gt; 1.7 per week previous test perform within 6 month confirm Baseline Visit Have minimum weekly creatinine clearance 45 litres previous test perform within 6 month confirm Baseline Visit Have D/P Creatinine ratio Peritoneal Equilibration Test 0.50 0.81 previous test perform within 6 month confirm Baseline Visit Have D/P Glucose ratio Peritoneal Equilibration Test 0.26 0.49 previous test perform within 6 month confirm Baseline Visit Be treat participate clinical Investigator period least three month Have understand sign Informed Consent Form . Have history drug alcohol abuse six month prior enter protocol Be treatment androgen Have Diabetes Mellitus ( defined American Diabetes Society , objectively document fast plasma glucose HbA1c determination ) Have clinically significant abnormal liver function test ( SGOT , SGPT , gammaGT &gt; 2 time upper normal limit ) Have acute infectious condition ( i.e . : pulmonary infection , acute hepatitis , high low urinary tract infection , renal parenchymal infection , pericarditis , etc ) Have history congestive heart failure clinically significant arrhythmia Have history epilepsy central nervous system disease Have malignancy within past 5 year , include lymphoproliferative disorder Have medical condition , judgment Investigator , would jeopardize patient 's safety follow exposure study drug , particularly patient 's life expectancy le 1 year Have history LCarnitine therapy use month prior enter protocol Have use investigational drug 3 month prior enter protocol Pregnant , lactating , fertility age without protection pregnancy adequate contraceptive mean</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Peritoneal dialysis</keyword>
	<keyword>L-carnitine</keyword>
</DOC>